Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00102050
Status:
COMPLETED
Last Update Posted:
2006-05-19
First Post:
2005-01-19
Brief Title:
Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication
Sponsor:
Nissan Chemical Industries
Organization:
Nissan Chemical Industries
Study Overview
Official Title:
A Double-Blind Randomized Parallel Group Placebo-Controlled Study to Evaluate the Safety and Efficacy of NM-702 in Subjects With Intermittent Claudication
Status:
COMPLETED
Status Verified Date:
2006-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
NM-702 oral tablets are being developed for the treatment of Intermittent Claudication a primary early stage indication of peripheral arterial disease PAD This trial is designed to assess the safety and efficacy of 4 mg andor 8 mg NM-702 taken twice a day BID for 24 weeks to see if it improves peak walking time PWT more than placebo for the treatment of Intermittent Claudication
Detailed Description:
NM-702 oral tablets are being developed for the treatment of Intermittent Claudication a primary early stage indication of peripheral arterial disease PAD This trial is designed to assess the safety and efficacy of 4 mg andor 8 mg NM-702 BID for 24 weeks to see if it improves peak walking time PWT more than placebo for the treatment of Intermittent Claudication
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None